

NEOGEN CORP  
Form 8-K  
December 30, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of**

**The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported) December 23, 2015**

**NEOGEN CORPORATION**

**(Exact name of registrant as specified in its charter)**

**MICHIGAN**  
**(State or other jurisdiction**  
**of incorporation)**

**0-17988**  
**(Commission**  
**File Number)**

**38-2367843**  
**(IRS Employer**  
**Identification No.)**

**620 Leshier Place Lansing, Michigan**  
**(Address of principal executive offices)**

**48912**  
**(Zip Code)**

Edgar Filing: NEOGEN CORP - Form 8-K

Registrant's telephone number, including area code 517-372-9200

**(Former name or former address, if changed since last report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 2.01 Completion of Acquisition or Disposition of Assets**

On December 23, 2015, Neogen Corporation ( Company ) issued a press release announcing that, effective that same date, it had acquired the complete rodenticide assets of Virbac Corporation, the North American affiliate of the France-based Virbac Group, a global animal health company. The acquired assets include a key rodenticide active ingredient that complements Neogen's existing active ingredients, and more than 40 regulatory approvals for a variety of formulations in the United States, Canada and Mexico. The acquired assets also include a large retail and OEM customer base. The formulations will be produced at the Company's existing facilities in Randolph, Wisconsin.

A copy of the press release is attached as Exhibit 99.1 to this report. This Form 8-K and the attached exhibit shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not incorporated by reference into any filing of the Registrant, whether made before or after the date of this report, regardless of any general incorporation language in the filing.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

99.1 Press Release dated December 23, 2015

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NEOGEN CORPORATION  
(Registrant)

Date: December 30, 2015

/s/ Steven J. Quinlan  
Steven J. Quinlan  
Vice President & CFO